Cartesian Therapeutics Announces New Employment Inducement Grants Jan 6, 2026 07:05AM
Cartesian Therapeutics appoints Adrian Bot to board of directors Dec 18, 2025 04:05PM
Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors Dec 18, 2025 04:05PM
Cartesian reports positive SLE trial results, expands into myositis Nov 13, 2025 04:06PM
Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis Nov 13, 2025 04:05PM
View Older Stories

Nov 6, 2025 07:00AM Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Oct 30, 2025 07:05AM Cartesian Therapeutics Announces New Employment Inducement Grants
Oct 30, 2025 07:01AM Cartesian Therapeutics names CEO Carsten Brunn as board chairman
Oct 30, 2025 07:00AM Cartesian Therapeutics Announces Carsten Brunn, Ph.D., Named as Chairman of the Company’s Board of Directors
Oct 3, 2025 07:05AM Cartesian Therapeutics Announces New Employment Inducement Grant
Aug 28, 2025 07:00AM Cartesian Therapeutics to Participate in Upcoming Investor Conferences
Aug 7, 2025 07:00AM Cartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Aug 5, 2025 07:05AM Cartesian Therapeutics Announces New Employment Inducement Grants
Jun 3, 2025 07:05AM Cartesian Therapeutics Announces New Employment Inducement Grants
May 30, 2025 07:01AM Cartesian Therapeutics (RNAC) Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis
May 30, 2025 07:00AM Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis
May 13, 2025 07:00AM Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
May 8, 2025 07:00AM Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 2, 2025 07:05AM Cartesian Therapeutics Announces New Employment Inducement Grants
Apr 8, 2025 07:01AM Cartesian Therapeutics' (RNAC) Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial
Apr 8, 2025 07:00AM Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial
Apr 2, 2025 07:05AM Cartesian Therapeutics Announces New Employment Inducement Grants
Apr 1, 2025 07:00AM Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Mar 13, 2025 07:00AM Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
Mar 6, 2025 07:05AM Cartesian Therapeutics Announces New Employment Inducement Grant
Feb 18, 2025 07:00AM Cartesian Therapeutics to Participate in Upcoming Investor Conferences
Feb 6, 2025 07:05AM Cartesian Therapeutics Announces New Employment Inducement Grants
Jan 27, 2025 07:00AM Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis
Jan 13, 2025 07:00AM Cartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of mRNA Cell Therapies for Autoimmune Diseases
Jan 7, 2025 07:05AM Cartesian Therapeutics Announces New Employment Inducement Grants
Dec 18, 2024 07:05AM Cartesian Therapeutics Announces New Employment Inducement Grants
Dec 3, 2024 06:01AM Cartesian Therapeutics (RNAC) Reports Positive Updated Results from Phase 2b Trial of Descartes-08
Dec 3, 2024 06:00AM Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial
Nov 21, 2024 07:00AM Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit
Nov 8, 2024 07:05AM Cartesian Therapeutics Announces New Employment Inducement Grants
Nov 7, 2024 07:00AM Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Nov 5, 2024 09:00AM Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting
Oct 15, 2024 07:03AM Cartesian Therapeutics (RNAC) Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis
Oct 15, 2024 07:00AM Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting
Oct 4, 2024 07:05AM Cartesian Therapeutics Announces New Employment Inducement Grants
Sep 9, 2024 07:03AM Cartesian Therapeutics (RNAC) Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis
Sep 9, 2024 07:00AM Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis
Sep 6, 2024 07:05AM Cartesian Therapeutics Announces New Employment Inducement Grant
Sep 3, 2024 07:05AM Cartesian Therapeutics (RNAC) Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15
Sep 3, 2024 07:00AM Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15
Aug 26, 2024 07:00AM Cartesian Therapeutics to Participate in Upcoming Investor Conferences
Aug 8, 2024 07:00AM Cartesian Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Aug 7, 2024 04:05PM Cartesian Therapeutics Announces New Employment Inducement Grants
Jul 8, 2024 04:05PM Cartesian Therapeutics Announces New Employment Inducement Grants
Jul 2, 2024 04:07PM Cartesian Therapeutics (RNAC) Appoints Kemal Malik to its Board
Jul 2, 2024 04:05PM Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik
Jul 2, 2024 06:32AM Cartesian Therapeutics (RNAC) Doses First Patient in Phase 2 Trial of Descartes-08
Jul 2, 2024 06:31AM Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus
Jul 2, 2024 06:30AM Cartesian Therapeutics (RNAC) Reports Positive Topline Results from Phase 2b Trial of Descartes-08
Jul 2, 2024 06:30AM Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis
View Older Stories